HELIOS Klinikum Bad Saarow GmbH — Clinical Trial Site

45 Registered trials

19 Currently recruiting

Organisation

HELIOS Klinikum Bad Saarow GmbH

Location

Bad Saarow, Germany

Identifier

ORG-100019121

Address

Pieskower Strasse 33, 15526, Germany

Departments

#2060:Klinik für Hämatologie
2519: Haema Onkologie
Clinic for Oncology and Palliative Care
Department for Oncology and Palliative Care
Department of Oncology and Palliative Care
Hämatologie, Onkologie und Palliativmedizin
Hematology
Klinik fuer Haematologie, Onkologie und Palliativmedizin
Klinik fuer Onkologie und Palliativmedizin
Klinik für Hämatologie
Klinik für Hämatologie, Onkologie und Palliativmedizin
Klinik für Hämatologie/Onkologie und Palliativmedizin
Klinik für Innere III
Klinik für Innere III - Hämatologie, Onkologie und Palliativmedizin
Klinik für Onkologie und Palliativmedizin
Klinik für Onkologie und Palliativmedizin Klinik für Hämatologie
N/A
nternal Medicine and Hematology and Oncology
Oncology
Oncology and Palliative Care
Onkologie und Palliativmedizin
Onkologisches Zentrum
Ost-Brandenburgisches Tumorzentrum e.V.
Sarkomzentrum

Clinical trials at this site (45)

Search interface

Use of the chemotherapy FOLFIRI and cetuximab if given with treatment breaks or continuously in patients with newly diagnosed metastatic col… Pending

2025-522377-12-00 metastatic colorectal cancer 5
A Study of Vepugratinib (LY3866288) in Participants with Cancer in the Urinary Tract ( FORAGER-2 ) Pending

2025-522855-25-00 Urinary Bladder Neoplasms 5
Accelerate Improvement in Multiple Myeloma for Newly Diagnosed Transplant-Eligible Patients (AugMMent) Pending

2025-523990-40-00 Newly diagnosed Multiple Myeloma in patients eligible f 5
Studies testing Ziftomenib together with standard treatments in adults with newly diagnosed acute myeloid leukemia (AML) that has specific g… Recruiting

2025-521314-25-00 NPM1-m and KMT2A-r Acute Myeloid Leukemia 5 2026-03-19
Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in… Recruiting

2025-521627-78-00 Neoplasms, Lung 5 2026-01-28
A study to investigate efficacy and safety of INT230-6 compared with US standard of care in participants aged ≥ 18 years old with metastatic… Recruiting

2024-512423-36-00 Leiomyosarcoma (non-uterine) 5 2024-11-20
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c… Recruiting

2023-507402-13-00 Multiple myeloma 5 2024-04-03
A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZU… Recruiting

2023-506414-46-00 High risk patients defined as having at least one of th 5 2022-04-22
A trial to learn how effective and safe datopotamab deruxtecan (Dato-DXd) is compared to docetaxel and how well Dato-DXd works in adults wit… Recruiting

2024-520101-39-00 TROP2 NMR-positive advanced or metastatic non-squamous 5 2026-04-01
ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid… Recruiting

2025-522395-92-00 metastatic oeso-gastric adenocarcinoma 5 2025-12-15
– IKF/AIO-QUINTIS – A Randomized Phase II Trial Evaluating Fruquintinib in Combination with Tislelizumab in Microsatellite Stable / Profici… Recruiting

2024-519929-38-00 Metastatic Colorectal Cancer without liver metastases 4 2025-10-27
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-line Treatment of PD-L1-high Metastatic Non-small Cell Lung… Recruiting

2024-517780-24-00 Lung Cancer 5 2025-09-18
ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) … Recruiting

2024-514030-20-00 colorectal cancer 4 2025-08-29
A trial comparing the treatment of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan to the standard treatment in patients with… Recruiting

2024-512583-57-00 HER2-positive locally advanced or metastatic gastric or 5 2025-07-30
Ivosidenib in participants with locally advanced or metastatic conventional chondrosarcoma untreated or previously treated with 1 or 2 syste… Recruiting

2023-508507-20-00 Locally advanced or metastatic conventional chondrosarc 5 2025-04-03
Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multi… Recruiting

2023-508076-11-00 Colon cancer staged T3-4 and/or nodal positive by CT an 5 2025-04-01
A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting

2024-517966-40-00 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::AB 4 2023-07-13
A Randomized, Placebo‐Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Di… Recruiting

2023-507518-28-00 Acute myeloid leukemia 5 2022-09-13
Asciminib Roll-over Study Recruiting

2023-507557-16-00 chronic myelogenous leukemia (CML) or Philadelphia Chro 5 2022-08-31
International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma Recruiting

2022-501180-40-00 Ewing Sarcoma 5 2022-06-17
Post-resection/ ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418). Prospective, randomized,… Recruiting

2024-512174-10-00 metastatic colorectal cancer 5 2021-11-11
Phase III study comparing Trabectedin (T) versus T plus tTF-NGR to entrap T inside the tumor in patients with metastatic and/or refractory s… Recruiting

2024-516392-33-00 Patients (18-75 years) with metastatic and/or refractor 5 2021-09-17
Public Title: Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Participants with M… Ended

2022-502975-45-00 Metastatic leiomyosarcoma 5 2023-12-12
Perioperative/Adjuvant atezolizumab in patients with MSI-high or MMRdeficient stage II high risk or stage III colorectal cancer ineligible f… Ended

2024-515224-37-00 Patients with MSI-high or MMR-deficient stage III color 4 2023-08-29